Cargando…
HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development
The prediction of response to drugs before initiating therapy based on transcriptome data is a major challenge. However, identifying effective drug response label data costs time and resources. Methods available often predict poorly and fail to identify robust biomarkers due to the curse of dimensio...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909422/ https://www.ncbi.nlm.nih.gov/pubmed/36776339 http://dx.doi.org/10.3389/fonc.2023.1047556 |
_version_ | 1784884573705863168 |
---|---|
author | Huang, Yue Rong, Zhiwei Zhang, Liuchao Xu, Zhenyi Ji, Jianxin He, Jia Liu, Weisha Hou, Yan Li, Kang |
author_facet | Huang, Yue Rong, Zhiwei Zhang, Liuchao Xu, Zhenyi Ji, Jianxin He, Jia Liu, Weisha Hou, Yan Li, Kang |
author_sort | Huang, Yue |
collection | PubMed |
description | The prediction of response to drugs before initiating therapy based on transcriptome data is a major challenge. However, identifying effective drug response label data costs time and resources. Methods available often predict poorly and fail to identify robust biomarkers due to the curse of dimensionality: high dimensionality and low sample size. Therefore, this necessitates the development of predictive models to effectively predict the response to drugs using limited labeled data while being interpretable. In this study, we report a novel Hierarchical Graph Random Neural Networks (HiRAND) framework to predict the drug response using transcriptome data of few labeled data and additional unlabeled data. HiRAND completes the information integration of the gene graph and sample graph by graph convolutional network (GCN). The innovation of our model is leveraging data augmentation strategy to solve the dilemma of limited labeled data and using consistency regularization to optimize the prediction consistency of unlabeled data across different data augmentations. The results showed that HiRAND achieved better performance than competitive methods in various prediction scenarios, including both simulation data and multiple drug response data. We found that the prediction ability of HiRAND in the drug vorinostat showed the best results across all 62 drugs. In addition, HiRAND was interpreted to identify the key genes most important to vorinostat response, highlighting critical roles for ribosomal protein-related genes in the response to histone deacetylase inhibition. Our HiRAND could be utilized as an efficient framework for improving the drug response prediction performance using few labeled data. |
format | Online Article Text |
id | pubmed-9909422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99094222023-02-10 HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development Huang, Yue Rong, Zhiwei Zhang, Liuchao Xu, Zhenyi Ji, Jianxin He, Jia Liu, Weisha Hou, Yan Li, Kang Front Oncol Oncology The prediction of response to drugs before initiating therapy based on transcriptome data is a major challenge. However, identifying effective drug response label data costs time and resources. Methods available often predict poorly and fail to identify robust biomarkers due to the curse of dimensionality: high dimensionality and low sample size. Therefore, this necessitates the development of predictive models to effectively predict the response to drugs using limited labeled data while being interpretable. In this study, we report a novel Hierarchical Graph Random Neural Networks (HiRAND) framework to predict the drug response using transcriptome data of few labeled data and additional unlabeled data. HiRAND completes the information integration of the gene graph and sample graph by graph convolutional network (GCN). The innovation of our model is leveraging data augmentation strategy to solve the dilemma of limited labeled data and using consistency regularization to optimize the prediction consistency of unlabeled data across different data augmentations. The results showed that HiRAND achieved better performance than competitive methods in various prediction scenarios, including both simulation data and multiple drug response data. We found that the prediction ability of HiRAND in the drug vorinostat showed the best results across all 62 drugs. In addition, HiRAND was interpreted to identify the key genes most important to vorinostat response, highlighting critical roles for ribosomal protein-related genes in the response to histone deacetylase inhibition. Our HiRAND could be utilized as an efficient framework for improving the drug response prediction performance using few labeled data. Frontiers Media S.A. 2023-01-26 /pmc/articles/PMC9909422/ /pubmed/36776339 http://dx.doi.org/10.3389/fonc.2023.1047556 Text en Copyright © 2023 Huang, Rong, Zhang, Xu, Ji, He, Liu, Hou and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Huang, Yue Rong, Zhiwei Zhang, Liuchao Xu, Zhenyi Ji, Jianxin He, Jia Liu, Weisha Hou, Yan Li, Kang HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development |
title | HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development |
title_full | HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development |
title_fullStr | HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development |
title_full_unstemmed | HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development |
title_short | HiRAND: A novel GCN semi-supervised deep learning-based framework for classification and feature selection in drug research and development |
title_sort | hirand: a novel gcn semi-supervised deep learning-based framework for classification and feature selection in drug research and development |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909422/ https://www.ncbi.nlm.nih.gov/pubmed/36776339 http://dx.doi.org/10.3389/fonc.2023.1047556 |
work_keys_str_mv | AT huangyue hirandanovelgcnsemisuperviseddeeplearningbasedframeworkforclassificationandfeatureselectionindrugresearchanddevelopment AT rongzhiwei hirandanovelgcnsemisuperviseddeeplearningbasedframeworkforclassificationandfeatureselectionindrugresearchanddevelopment AT zhangliuchao hirandanovelgcnsemisuperviseddeeplearningbasedframeworkforclassificationandfeatureselectionindrugresearchanddevelopment AT xuzhenyi hirandanovelgcnsemisuperviseddeeplearningbasedframeworkforclassificationandfeatureselectionindrugresearchanddevelopment AT jijianxin hirandanovelgcnsemisuperviseddeeplearningbasedframeworkforclassificationandfeatureselectionindrugresearchanddevelopment AT hejia hirandanovelgcnsemisuperviseddeeplearningbasedframeworkforclassificationandfeatureselectionindrugresearchanddevelopment AT liuweisha hirandanovelgcnsemisuperviseddeeplearningbasedframeworkforclassificationandfeatureselectionindrugresearchanddevelopment AT houyan hirandanovelgcnsemisuperviseddeeplearningbasedframeworkforclassificationandfeatureselectionindrugresearchanddevelopment AT likang hirandanovelgcnsemisuperviseddeeplearningbasedframeworkforclassificationandfeatureselectionindrugresearchanddevelopment |